IFNB1 and myeloid sarcoma: Since the MS population included some patients who were on immunomodulatory therapy, we examined if sensitivity to apoptosis was different between MS patients who were untreated (7) when compared to those on either beta interferon(5), glatiramer acetate (3), methotrexate (2), or mycophenalate (1).